Radicava (edaravone) listed under Exceptional Access Program in Ontario

May 28, 2020 – The province of Ontario has listed Radicava (edaravone) on the public formulary as a therapy accessible through the Ontario Drug Benefit Formulary Exceptional Access Program (EAP) as a treatment for ALS. This decision comes approximately one month after the conclusion of pCPA negotiations and demonstrates that working together we can make a difference. If you live in Ontario and are interested in accessing the therapy, connect with your ALS neurologist to understand any conditions for coverage.

To date, only two provinces — Quebec and Ontario — have made reimbursement decisions so far.

Learn more about how Canadians are advocating for equitable, timely and affordable access to Radicava here.